| | |
Geno-type
|
Symptoms
| | | |
|---|
| | | |
Yes (N)
|
No (N)
|
ORb
|
95% CI
|
Pc*
|
|---|
|
EYES
|
|
Exposed
|
NAT1
|
IM+S
|
33
|
53
|
1.0
|
-
|
0.067
|
| | |
R
|
23
|
17
|
2.2
|
1.0–4.9
| |
|
Unexposed
|
NAT1
|
IM+S
|
19
|
60
|
1.0
|
-
| |
| | |
R
|
6
|
27
|
0.63
|
0.22–1.9
| |
|
Exposed
|
SULT1A1
R213H
|
GG
|
27
|
14
|
1.0
|
-
|
0.19
|
| | |
AG+AA
|
29
|
56
|
0.22
|
0.096–0.52
| |
|
Unexposed
|
SULT1A1
R213H
|
GG
|
13
|
31
|
1.0
| | |
| | |
AG+AA
|
12
|
56
|
0.56
|
0.22–1.4
| |
|
Exposed
|
TNF
-308
|
GG
|
36
|
44
|
1.0
|
-
|
0.11
|
| | |
GA+AA
|
17
|
19
|
1.0
|
0.47–2.4
| |
|
Unexposed
|
TNF
-308
|
GG
|
11
|
57
|
1.0
|
-
| |
| | |
GA+AA
|
14
|
25
|
2.6
|
1.0–7.0
| |
|
WHEEZE
|
|
Exposed
|
CYP1A1
*2B
|
I/I
|
34
|
87
|
1.0
|
-
|
0.061
|
| | |
I/V
|
5
|
1
|
14
|
1.5–130
| |
|
Unexposed
|
CYP1A1
*2B
|
I/I
|
23
|
82
|
1.0
|
-
| |
| | |
I/V
|
1
|
6
|
0.83
|
0.090–7.7
| |
|
Exposed
|
SULT1A1
R213H
|
GG
|
17
|
25
|
1.0
|
-
|
0.58
|
| | |
AG+AA
|
22
|
63
|
0.52
|
0.22–1.2
| |
|
Unexposed
|
SULT1A1
R213H
|
GG
|
14
|
30
|
1.0
|
-
| |
| | |
AG+AA
|
10
|
58
|
0.38
|
0.15–0.99
| |
|
Exposed
|
CCL5
-403
|
GG
|
19
|
64
|
1.0
|
-
|
0.42
|
| | |
AG+AA
|
20
|
21
|
3.1
|
1.3–7.1
| |
|
Unexposed
|
CCL5
-403
|
GG
|
13
|
58
|
1.0
|
-
| |
| | |
AG+AA
|
10
|
29
|
1.8
|
0.68–5.0
| |
|
Exposed
|
TNF
-308
|
GG
|
29
|
52
|
1.0
|
-
|
0.043
|
| | |
GA+AA
|
7
|
30
|
0.37
|
0.14–0.99
| |
|
Unexposed
|
TNF
-308
|
GG
|
13
|
55
|
1.0
|
-
| |
| | |
GA+AA
|
10
|
29
|
1.3
|
0.46–3.4
| |
|
DRY COUGH
|
|
Exposed
|
HLADQB1
*05
|
Absent
|
20
|
62
|
1.0
|
-
|
0.047
|
| | |
Present
|
18
|
20
|
2.7
|
1.2–6.3
| |
|
Unexposed
|
HLADQB1
*05
|
Absent
|
12
|
74
|
1.0
|
-
| |
| | |
Present
|
1
|
23
|
0.27
|
0.031–2.2
| |
|
Exposed
|
TNF
-308
|
GG
|
30
|
50
|
1.0
|
-
|
0.023
|
| | |
GA+AA
|
7
|
28
|
0.43
|
0.17–1.1
| |
|
Unexposed
|
TNF
-308
|
GG
|
6
|
62
|
1.0
|
-
| |
| | |
GA+AA
|
7
|
32
|
2.2
|
0.66–7.3
| |
|
COUGH WITH MUCUS
|
|
Exposed
|
GSTM1
|
Present
|
19
|
45
|
1.0
|
-
|
0.13
|
| | |
Absent
|
24
|
39
|
1.4
|
0.66–3.0
| |
|
Unexposed
|
GSTM1
|
Present
|
8
|
55
|
1.0
|
-
| |
| | |
Absent
|
18
|
31
|
3.5
|
1.3–9.4
| |
|
Exposed
|
GSTM3
|
AA
|
29
|
61
|
1.0
|
-
|
0.028
|
| | |
AB+BB
|
14
|
23
|
1.2
|
0.52–2.7
| |
|
Unexposed
|
GSTM3
|
AA
|
23
|
53
|
1.0
|
-
| |
| | |
AB+BB
|
3
|
33
|
0.22
|
0.059–0.81
| |
|
Exposed
|
GSTP1
*105
|
I/I
|
26
|
41
|
1.0
|
-
|
0.019
|
| | |
I/V+V/V
|
17
|
43
|
0.66
|
0.32–1.4
| |
|
Unexposed
|
GSTP1
*105
|
I/I
|
8
|
48
|
1.0
|
-
| |
| | |
I/V+V/V
|
18
|
38
|
3.0
|
1.1–8.0
| |
|
Exposed
|
CCL5
-403
|
GG
|
22
|
59
|
1.0
|
-
|
0.079
|
| | |
AG+AA
|
21
|
20
|
2.9
|
1.3–6.5
| |
|
Unexposed
|
CCL5
-403
|
GG
|
17
|
54
|
1.0
|
-
| |
| | |
AG+AA
|
8
|
31
|
0.86
|
0.32–2.3
| |
|
NOSE BLEED
|
|
Exposed
|
MPO
|
GG
|
25
|
65
|
1.0
|
-
|
0.018
|
| | |
AG+AA
|
3
|
30
|
0.21
|
0.056–0.94
| |
|
Unexposed
|
MPO
|
GG
|
3
|
70
|
1.0
|
-
| |
| | |
AG+AA
|
4
|
35
|
2.9
|
0.58–14
| |
-
a Adjusted effect estimates (for sex, age, atopy, and smoking) are presented as odds ratios (OR) and 95% confidence intervals. Statistically significant results are presented in bold.
-
bAll results that reached statistical significance with respect to genotype-associated risk in either exposure-strata, or in the analysis of interaction between genotype and exposure status, are presented.
-
cAnalysis of interaction between exposure and genotype was performed in a separate model using logistic regression with interaction term. P-values regarding interaction between exposure and genotype are indicated by P*.
